Shanghai Pharmaceuticals Holding (Zhejiang) Co., Ltd.

Zhejiang Shangyao Xinxin Pharmaceutical Co., Ltd. (formerly Zhejiang Xinxin Pharmaceutical Co., Ltd.) was approved for establishment in January 2005 and is one of the first batch of pharmaceutical wholesale enterprises in Zhejiang Province equipped with modern logistics facilities. In April 2012, the company completed asset restructuring and became one of the core holding enterprises of Shanghai Pharmaceuticals Distribution Holding Co., Ltd. in Zhejiang.
The company has a registered capital of RMB 37.88 million. Its registered address is 2/F, No. 8 Meihuabei, Shangcheng District, Hangzhou. Its logistics center is located at 2/F, Building 1, Hangzhou Huaye High-tech Industrial Park, No. 1180 Bin'an Road, Binjiang District, Hangzhou. The company has the following internal departments: Manager's Office, Administration Office, Quality Management Department, Finance Department, Planning and Procurement Department, Sales Department, Pharmaceutical Business Development Department, Medical Device Department and Logistics Department. The company's business scope includes: Chinese patent medicines, chemical pharmaceutical preparations, antibiotics, biochemical drugs, biopharmaceuticals, medical devices, etc.
The company operates under a general manager responsibility system under the leadership of the board of directors. The company currently has 54 employees, 25 of whom have obtained various vocational and technical qualification certificates, and 4 licensed pharmacists. The company's office area is 1,199 square meters, and its warehouse area exceeds 1,700 square meters. It is a pharmaceutical warehousing and logistics center built in strict accordance with GSP requirements for pharmaceutical wholesale enterprises.
The company's business philosophy is "sincere cooperation, creating win-win results together." Its service purpose is "to provide high-quality and efficient medicines to meet patients' needs for therapeutic medication." Its quality policy is "quality first, service paramount, standardized management, honest operation."
With its accurate positioning and high-quality services, the company has established good strategic cooperative relationships with more than ten multinational pharmaceutical companies, including AstraZeneca, Astellas, Bayer, Baxter Healthcare, Pfizer, Roche, SciClone Pharmaceuticals (USA), Novartis, Bristol-Myers Squibb, MSD, Abbott and GlaxoSmithKline, as well as large domestic pharmaceutical companies such as CSPC Pharmaceutical Group, Jiangsu Simcere, Jiangsu Hansoh, Jiangsu Aosaikang, Guizhou Yibai and Biotech Pharmaceutical. The company will uphold the corporate spirit of "integrity, innovation, dedication and enterprise," correctly grasp the pulse of the market and development direction, accurately identify market positioning, integrate with actual conditions, follow a path of "characteristic development," continuously enhance the company's reputation and maximize customer satisfaction.
From now on, as a core member of Shanghai Pharmaceuticals in Zhejiang Province, the company will become a company featuring first-class specialty and professional products within the province and well-known domestically, mainly cooperating with imported and joint-venture supplier products, focusing on pure sales covering county-level and above medical institutions. It will not only seek the products and provide the services that hospital customers need, but more importantly, build a bridge between manufacturers and hospitals.
In 2011, the company achieved tax-inclusive sales of RMB 669 million, a year-on-year increase of 25.50%, and achieved profits and taxes of more than RMB 20 million, a year-on-year increase of 20%. The company operates in accordance with the management requirements of a modern pharmaceutical enterprise, achieving both corporate benefits and social benefits. It strives to achieve sales of RMB 850 million in 2012 and annual sales exceeding RMB 2.5 billion in 2016.
After asset restructuring, the company has successfully achieved transformation and upgrading, fundamentally solving the bottlenecks faced by many small and medium-sized pharmaceutical enterprises, such as difficulty in financing and difficulty in introducing products. It will fully rely on the many advantages of Shanghai Pharmaceuticals in talent, R&D, marketing, capital and branding, as well as its own accumulated value and resources, to achieve healthier, faster and more sustainable development.